Skip to main content
letter
. 2021 May 5;39(3):428–431. doi: 10.1002/hon.2872

TABLE 1.

Characteristics of 25 Hematologic patients with COVID‐19

No. of cases 25
Sex (M/F) 12/13
Median age‐years (range) 59 (21–85)
Hematologic malignancies

  • Lymphoma

 10/25 (40%)

  • Myeloma

 7/25 (28%)

  • Chronic lymphoid leukemia (CLL)

 5/25 (20%)

  • Acute leukemia

 3/25 (12%)
Concomitant therapy

  • Chemotherapy (CHT)

 10/25 (40%)

  • Steroids

 5/25 (20%)

  • Rituximab ± CHT

 4/25 (16%)

  • Daratumomab ± CHT

 4/25 (16%)

  • Ibrutinib or venetoclax

 3/25 (12%)
2/25 (8%)
Immunoglobulins, b mg/dl‐ median (range)

  • IgG

 832 (167–2210)

  • IgM

 54,5 (6–2510)

  • IgA

 54 (8–605)
Lymphocytes b , N/mmc‐median (range) 1100 (250–3300)
a

1 Nivolumab; 1 Ponatinib and prednisone.

b

Median values at SARS‐CoV‐2 infection onset.